Skip to main content
MarketStoryBook
All stories4578.T in “America Imports the World's Drug Prices”4578.T in stories4578.T stock

4578.T in “America Imports the World's Drug Prices”

Otsuka Holdings Co., Ltd.

Bear sideStableExposure: not rated yet

Otsuka's premium-priced CNS and rare-disease portfolio, including Rexulti and Jynarque, is exposed to lower US prices and tougher launch sequencing decisions.

4578.T impact map — “America Imports the World's Drug Prices”

How this story travels from the headline to 4578.T’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading 4578.T impact map…

Price history, marked with story events

Oct 14, 2025 – Oct 13, 2026 · 242 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

America Imports the World's Drug Prices

US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

BEAR side — Otsuka's premium-priced CNS and rare-disease portfolio, including Rexulti and Jynarque, is exposed to lower US prices and tougher launch sequencing decisions.

Read the full America Imports the World's Drug Prices story

Bull side

0 stories

No bull-side stories for 4578.T yet.

Bear side

2 stories

  • 4578.T in “America Imports the World's Drug Prices”

    StableExposure: not rated yet
    Viewing

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Otsuka's premium-priced CNS and rare-disease portfolio, including Rexulti and Jynarque, is exposed to lower US prices and tougher launch sequencing decisions.

  • The Patent Cliff Sparks a Biotech Land Grab

    4578.T in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    Approaching exclusivity losses in core neuropsychiatric products leave Otsuka dependent on successful launches, licensing and acquisitions to replace concentrated revenue.